Vigo Luca, Senni Carlotta, Pellegrini Marco, Vagge Aldo, Ferro Desideri Lorenzo, Carones Francesco, Scorcia Vincenzo, Giannaccare Giuseppe
Carones Ophthalmology Center, Via Domodossola 19, 20145, Milan, Italy.
Department of Ophthalmology, University Vita-Salute-IRCCS Ospedale San Raffaele, Via Olgettina 60, 20132, Milan, Italy.
Ophthalmol Ther. 2022 Aug;11(4):1441-1447. doi: 10.1007/s40123-022-00518-7. Epub 2022 May 14.
Recently, there has been a progressive shift from simple water-adding medications towards complex multi-action combined formulas aimed at disrupting different mechanisms within the dry eye disease (DED) vicious cycle. This study evaluated the efficacy and tolerability of Trimix eye drops (Off Health Italia, Italy), a combination of viscosity-enhancing hyaluronic acid, trehalose, and cationic liposomes comprising stearylamine and phospholipids, in patients with DED.
In this prospective, pilot study patients diagnosed with mild to moderate DED were enrolled and treated with Trimix eye drops three times daily for 2 months. Ocular surface workup was performed before (V0) and after therapy (V1) by means of IDRA (SBM Sistemi, Turin, Italy), for the measurement of (i) noninvasive break-up time (NIBUT); (ii) tear meniscus height (TMH); (iii) lipid layer thickness (LLT); (iv) infrared meibography (percentage of meibomian gland loss); (v) bulbar redness (Efron scale). Treatment tolerability was scored on a visual analog scale ranging from 0 (none/not at all) to 100 (much/very) for eight questions. Ocular discomfort symptoms were scored using the Standard Patient Evaluation of Eye Dryness (SPEED) questionnaire.
Overall, 25 subjects (mean age 60.32 ± 14.55 years) were included in the study. At V1, TMH, NIBUT, and LLT significantly increased compared to V0 (from 0.29 ± 0.06 to 0.46 ± 0.06 mm, 6.34 ± 2.61 to 7.58 ± 2.52 s, and from 63.26 ± 17.15 to 68.42 ± 15.63 nm, respectively; all P < 0.04). Concerning ocular discomfort symptoms, SPEED score significantly improved at V1 (from 16.63 ± 6.32 to 8.30 ± 5.98; P < 0.001); moreover, treatment tolerability was high for all eight items investigated.
Two-month treatment with Trimix formulation improved objective signs and subjective symptoms in patients with DED, showing also a good tolerability profile.
最近,从单纯的加水型药物逐渐转向旨在打破干眼疾病(DED)恶性循环中不同机制的复杂多作用联合配方。本研究评估了Trimix滴眼液(意大利Off Health Italia公司)在DED患者中的疗效和耐受性,该滴眼液由增稠透明质酸、海藻糖以及包含硬脂胺和磷脂的阳离子脂质体组成。
在这项前瞻性试点研究中,纳入了诊断为轻度至中度DED的患者,并使用Trimix滴眼液每天滴眼3次,持续2个月。在治疗前(V0)和治疗后(V1)通过IDRA(意大利都灵SBM Sistemi公司)进行眼表检查,以测量:(i)无创泪膜破裂时间(NIBUT);(ii)泪河高度(TMH);(iii)脂质层厚度(LLT);(iv)红外睑板腺造影(睑板腺损失百分比);(v)球结膜充血(Efron评分)。对八个问题采用视觉模拟量表对治疗耐受性进行评分,范围从0(无/完全没有)到100(多/非常)。使用干眼标准患者评估(SPEED)问卷对眼部不适症状进行评分。
总体而言,25名受试者(平均年龄60.32±14.55岁)纳入本研究。在V1时,与V0相比TMH、NIBUT和LLT显著增加(分别从0.29±0.06增加到0.46±0.06毫米、从6.34±2.61增加到7.58±2.52秒、从63.26±17.15增加到68.42±15.63纳米;所有P<0.04)。关于眼部不适症状,V1时SPEED评分显著改善(从16.63±6.32降至8.30±5.98;P<0.001);此外,所研究的所有八个项目的治疗耐受性都很高。
Trimix配方进行两个月的治疗改善了DED患者的客观体征和主观症状,并且显示出良好耐受性。